{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chickenpox/prescribing-information/aciclovir/","result":{"pageContext":{"chapter":{"id":"17d5cf92-3449-52d5-932c-f1b770061787","slug":"aciclovir","fullItemName":"Aciclovir","depth":2,"htmlHeader":"<!-- begin field 58efdac2-f768-4bd8-88fc-8f4105d1527d --><h2>Aciclovir</h2><!-- end field 58efdac2-f768-4bd8-88fc-8f4105d1527d -->","summary":"","htmlStringContent":"<!-- begin item 8a9508b2-1877-42e7-820f-0466b6215680 --><!-- end item 8a9508b2-1877-42e7-820f-0466b6215680 -->","topic":{"id":"5d1b7a44-f7ff-52e9-a218-c53ecadb0e4c","topicId":"4960f8a4-0140-4c3b-9bd0-b1ac6fccd648","topicName":"Chickenpox","slug":"chickenpox","lastRevised":"Last revised in August 2018","chapters":[{"id":"fe0450ab-ddfd-5960-bb47-b986d9cc6059","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ff90f80f-13d4-5732-8d09-9c5566ce6ec2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"16ae9969-1384-5b7b-aff0-1ac19aeee530","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"10059b43-4a23-59cf-8f5f-31f8d5e8e3c9","slug":"changes","fullItemName":"Changes"},{"id":"5f0098ae-9d37-5658-9379-66477733f220","slug":"update","fullItemName":"Update"}]},{"id":"9d70228e-0283-5d34-a4af-5237097d0a02","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fa1d46ea-9d63-5d1a-b60c-9b96e87f802c","slug":"goals","fullItemName":"Goals"},{"id":"4e21e939-92fd-555c-a175-93b8a626169a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ea18d1e8-0bdd-542f-a985-2952ecabca2d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5d911096-5b50-551b-a17a-cff3070315b0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"601f7c68-386e-5474-96f1-d6239bd81750","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"305e8fa8-8eb6-5b69-a902-93019e0c2c17","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"bb9b11dc-3295-5e2b-9798-37bb8b6ebbc0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"145f102c-4e0f-52c9-8b3b-e0b5c6eb112e","slug":"definition","fullItemName":"Definition"},{"id":"9f4d0cad-78a8-568f-831e-8878d2f4bfd3","slug":"transmission","fullItemName":"Transmission"},{"id":"5691920a-f618-5a98-ab32-417dfc782db1","slug":"prevalence","fullItemName":"Prevalence"},{"id":"eb6a66b5-2006-5968-a97d-52de72842cbf","slug":"complications","fullItemName":"Complications"}]},{"id":"a3eb8e9b-cdd9-5243-8353-09aac3fdc322","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ff9f70a8-0c29-5357-946d-bbca67eafbbf","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b651c5b4-34df-5480-b05d-909c9023a7a5","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3844af91-e26b-515e-a645-9725d2f54810","fullItemName":"Management","slug":"management","subChapters":[{"id":"7700c175-994a-51d5-a2d0-36eb7478e2c1","slug":"child-or-adult","fullItemName":"Scenario: Child or adult"},{"id":"f6a62aa2-354d-5eee-a868-fb5d162115ef","slug":"pregnant-woman","fullItemName":"Scenario: Pregnant woman"},{"id":"c659257f-8875-5440-ae24-57c071cf226c","slug":"breastfeeding-woman","fullItemName":"Scenario: Breastfeeding woman"},{"id":"499e6045-af39-5bc4-952b-edcb6b29144f","slug":"neonate","fullItemName":"Scenario: Neonate"},{"id":"dac00668-b032-569c-8b5a-260c2f1625b3","slug":"immunocompromised","fullItemName":"Scenario: Immunocompromised"},{"id":"072ae3a5-9cf4-5233-bca1-2d46e53de42b","slug":"exposure-to-chickenpox","fullItemName":"Scenario: Exposure to chickenpox"}]},{"id":"fa12b54d-0c95-5ee8-8884-219ac7a9dd2a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a2d64426-afb7-5590-998d-3ed0d13b78d2","slug":"chlorphenamine","fullItemName":"Chlorphenamine"},{"id":"17d5cf92-3449-52d5-932c-f1b770061787","slug":"aciclovir","fullItemName":"Aciclovir"}]},{"id":"95550d9e-6be2-5a94-924a-c4c2f8e7dbe4","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"880099bb-bff8-543e-a1e8-267413ef45b9","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c80905f1-b771-5170-8be8-c1bcee935552","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6bf66548-b486-53e1-bce7-d9bb45af9bea","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"52168b40-dab0-5afb-9662-bb28014b5734","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5fa2da47-e83a-5886-9c1b-c6ae4e97a0a7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"769ea126-78ac-540c-a1c9-38446d44e22e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"87e1772a-0cd8-5e0c-ad7a-b676a65171bb","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"fa12b54d-0c95-5ee8-8884-219ac7a9dd2a","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"67cf7193-ae34-5d6b-b8fe-312f9aed4ccd","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 2cdeef92-ac0f-4e29-9cd2-6a61a052c32c --><h3>Adverse effects</h3><!-- end field 2cdeef92-ac0f-4e29-9cd2-6a61a052c32c -->","summary":"","htmlStringContent":"<!-- begin item 61359134-fa96-4add-b663-9e5082106ca7 --><!-- begin field 289ffe6f-030e-4f1c-8d93-4a360c5768de --><ul><li>Aciclovir is generally well tolerated. </li><li>However, it may cause gastrointestinal adverse effects, such as nausea, vomiting, diarrhoea, and abdominal pain. Headache, dizziness, and skin rashes (including photosensitivity and urticaria) have also been commonly reported.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">BNF 72, 2016</a>]</p><!-- end field 289ffe6f-030e-4f1c-8d93-4a360c5768de --><!-- end item 61359134-fa96-4add-b663-9e5082106ca7 -->","subChapters":[]},{"id":"67eca59c-6ae3-57ab-a93a-231ba651535f","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 3a71fc66-b072-419d-a87d-dd05e61089d8 --><h3>Contraindications and cautions</h3><!-- end field 3a71fc66-b072-419d-a87d-dd05e61089d8 -->","summary":"","htmlStringContent":"<!-- begin item 224ed2b8-85ef-4c91-aee6-7f6bd279d419 --><!-- begin field 37ff226a-0954-4b4a-b077-b7497d376b25 --><ul><li><strong>Do not prescribe aciclovir</strong> to a person with a known allergy to aciclovir or valaciclovir.</li><li><strong>Prescribe aciclovir with caution</strong> in a person who: <ul><li>Is elderly.</li><li>Has underlying neurological abnormalities.</li><li>Has severe liver or electrolyte abnormalities.</li><li>Has significant hypoxia.</li><li>Has renal impairment — advise the person to maintain adequate hydration. Dose adjustment is required.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">BNF 72, 2016</a>]</p><!-- end field 37ff226a-0954-4b4a-b077-b7497d376b25 --><!-- end item 224ed2b8-85ef-4c91-aee6-7f6bd279d419 -->","subChapters":[]},{"id":"1a64efc9-5709-5eb9-8dde-7e1c9e4d9a0e","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 114922e0-2105-4860-975d-f84cdfb35df2 --><h3>Drug interactions</h3><!-- end field 114922e0-2105-4860-975d-f84cdfb35df2 -->","summary":"","htmlStringContent":"<!-- begin item ff3a1b2d-6b18-4977-86bc-39cb90f1d4eb --><!-- begin field 7b955762-ff68-48c6-a092-b07dc793c3fa --><ul><li>There are no clinically significant drug interactions with aciclovir, although it may increase the plasma concentration of aminophylline and theophylline.</li><li>However, if other nephrotoxic drugs are used, the risk of renal impairment is increased.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">BNF 72, 2016</a>]</p><!-- end field 7b955762-ff68-48c6-a092-b07dc793c3fa --><!-- end item ff3a1b2d-6b18-4977-86bc-39cb90f1d4eb -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}